Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats

Clinical Science

Volumn 116, Issue 1, 2009, Pages 61-70

  Olearczyk, Jeffrey J ^a   Quigley, Jeffrey E ^a   Mitchell, Bradford C ^a   Yamamoto, Tatsuo ^b   Kim, In Hae ^c   Newman, John W ^c   Luria, Ayala ^c   Hammock, Bruce D ^c   Imig, John D ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Blood pressure; Diabetes; Eicosanoid; Inflammation; Nephropathy; Soluble epoxide hydrolase

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; ANGIOTENSIN II; ENZYME INHIBITOR; EPOXIDE HYDROLASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; 12-(3-ADAMANTAN-1-YLUREIDO)DODECANOIC ACID; ADAMANTANE; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; INSULIN; LAURIC ACID DERIVATIVE; LIPID;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EXCRETION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GOTO KAKIZAKI RAT; HISTOPATHOLOGY; HYPERTENSION; KIDNEY CORTEX; MACROPHAGE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; ANIMAL; BLOOD; DISEASE COURSE; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RAT STRAIN; URINE;

ADAMANTANE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HYPERTENSION; INSULIN; LAURIC ACIDS; LIPIDS; MALE; NF-KAPPA B; RATS; RATS, INBRED STRAINS;

EID: 60549106716     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080039     Document Type: Article

References (32)

1. (2003) USRDS: the United States Renal Data System. Am. J. Kidney Dis. 42 (Suppl. 5), 1-230
2. Mezzano, S., Aros, C., Droguett, A. et al. (2004) NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant 10, 2505-2512
3. Guijarro, C. and Egido, J. (2001) Transcription factor-κB (NF-κB) and renal disease. Kidney Int. 59, 415-424
4. Imig, J. D. (2000) Eicosanoid regulation of the renal vasculature. Am. J. Physiol. Renal Physiol. 279, F965-F981
5. Capdevila, J. H. and Falck, J. R. (2001) The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem. Biophys. Res. Commun. 285, 571-576
6. Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185
7. Node, K., Huo, Y., Ruan, X. et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279
8. Campbell, W. B. (2000) New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol. Sci. 21, 125-127
9. Imig, J. D. (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289, F496-F503
10. Morisseau, C., Goodrow, M. H., Dowdy, D. et al. (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. U.S.A. 96, 8849-8854
11. Kim, I. H., Morisseau, C., Watanabe, T. and Hammock, B. D. (2004) Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47, 2110-2122
12. Moghaddam, M. F., Grant, D. F., Cheek, J. M., Greene, J. F., Williamson, K. C. and and Hammock, B. D. (1997) Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat. Med. 3, 562-566
13. Zhao, X., Yamamoto, T., Newman, J.W. et al. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15, 1244-1253
14. Newman, J. W., Watanabe, T. and Hammock, B. D. (2002) The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J. Lipid Res. 43, 1563-1578
15. Watanabe, T., Morisseau, C., Newman, J. W. and Hammock, B. D. (2003) In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab. Dispos. 31, 846-853
16. Sowers, J. R. and Epstein, M. (1995) Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 26, 869-879
17. Viberti, G. C. and Earle, K. (1992) Predisposition to essential hypertension and the development of diabetic nephropathy. J. Am. Soc. Nephrol. 3, S27-S33
18. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694
19. Movassat, J., Saulnier, C., Serradas, P. and Portha, B. (1997) Impaired development of pancreatic β-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 40, 916-925
20. Picarel-Blanchot, F., Berthelier, C., Bailbe, D. and Portha, B. (1996) Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. Am. J. Physiol. 271, E755-E762
21. Kim, C. S., Sohn, E. J., Kim, Y. S. et al. (2007) Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. J. Ethnopharmacol. 111, 240-247
22. Smith, K. R., Pinkerton, K. E., Watanabe, T., Pedersen, T. L., Ma, S. J. and Hammock, B. D. (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 102, 2186-2191
23. Schmelzer, K. R., Kubala, L., Newman, J. W., Kim, I. H., Eiserich, J. P. and and Hammock, B. D. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 102, 9772-9777
24. Yu, Z., Xu, F., Huse, L. M., Morisseau, C. et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992-998
25. Imig, J. D., Zhao, X., Zharis, C. et al. (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 1-7
26. Cheng, Z. J., Vaskonen, T., Tikkanen, I. et al. (2001) Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37, 433-439
27. Tefescu, A., Kanazawa, M., Ishida, A. et al. (2008) Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy. J. Hypertens. 26, 312-321
28. Janssen, U., Riley, S. G., Vassiliadou, A., Floege, J. and Phillips, A. O. (2003) Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 63, 2162-2170
29. Fang, X., Hu, S., Watanabe, T. et al. (2005) Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J. Pharmacol. Exp. Therap. 314, 260-270
30. Fang, X., Kaduce, T. L., Weintraub, N. L. et al. (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells: implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276, 14867-14874
31. Weintraub, N. L., Fang, X., Kaduce, T. L., VanRollins, M., Chatterjee, P. and Spector, A. A. (1999) Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am. J. Physiol. Heart Circ. Physiol. 277, H2098-H2108
32. Imig, J. D. (2006) Eicosanoids and renal vascular function in diseases. Clin. Sci. 111, 21-34